Log In
Print this Print this

milatuzumab-doxorubicin conjugate

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized anti-CD74 antibody conjugated to doxorubicin
Molecular Target CD74 molecule major histocompatibility complex class II invariant chain
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today